{"id":"W4403239841","doi":"10.1136/ijgc-2024-005919","title":"GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Verastem Oncology; GOG Foundation; Australia New Zealand Gynaecological Oncology Group; GlaxoSmithKline; AstraZeneca","keywords":"Medicine; Ovarian cancer; Serous fluid; Regimen; Oncology; Internal medicine; Discontinuation; KRAS; Tolerability; Clinical trial; Clinical endpoint; Progression-free survival; Adverse effect; Cancer; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007067393,0.0004151829,0.001514762,0.0003993467,0.00004886877,0.00009279328,0.0002456688,0.0001373124,0.001381336],"category_scores_gemma":[0.0008080648,0.0002325378,0.0003670653,0.0003985309,0.0002243128,0.0001806356,0.00004184706,0.00046716,0.000003236162],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003860491,"about_ca_system_score_gemma":0.002933203,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001028344,"about_ca_topic_score_gemma":0.0008159216,"domain_scores_codex":[0.9962154,0.0003443641,0.00132384,0.0004721908,0.001289384,0.0003548214],"domain_scores_gemma":[0.9959885,0.001584362,0.0009486194,0.0001793809,0.0009271101,0.0003719936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.821821,0.005537761,0.09919827,0.0001232374,0.005641603,0.0005053148,0.001057762,0.004102197,0.00007046101,0.0001354438,0.0004114153,0.06139552],"study_design_scores_gemma":[0.9137107,0.01724959,0.05990282,0.002534781,0.001559025,0.00003164865,0.00007236427,0.002596101,0.0003975327,0.00009425233,0.001547257,0.0003038806],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897197,0.00232512,0.00006108808,0.003303265,0.001996953,0.002261678,0.0001766231,0.00002547552,0.0001300255],"genre_scores_gemma":[0.996146,0.0007214915,0.001070068,0.000409825,0.0006837534,0.0008178045,0.00005450649,0.0000369316,0.00005959061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09188972,"threshold_uncertainty_score":0.9999635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07159507315498903,"score_gpt":0.4099690937908886,"score_spread":0.3383740206358996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}